Literature DB >> 30343279

Novel Combination of Arsenic Trioxide (As2O3) Plus Resveratrol in Inducing Programmed Cell Death of Human Neuroblastoma SK-N-SH Cells.

Chun-Ming Yen1,2, Chia-Wen Tsai3, Wen-Shin Chang3, Yi-Chin Yang4, Yi-Wen Hung4, Hsu-Tung Lee2, Chiung-Chyi Shen2, Meei-Ling Sheu4,5, Ju-Yu Wang6, Chi-Li Gong7, Wen-Yu Cheng8,9, DA-Tian Bau7,10,11.   

Abstract

AIM: Arsenic trioxide (As2O3), known as pi-shuang and the most toxic compound in traditional Chinese medicine, has been used as an antitumor agent for thousands of years. Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a natural phenol that has significant anti-bacterial, anti-fungaI and antiaging activities. Our study aimed to examine the combined anticancer effects of As2O3 and resveratrol against human neuroblastoma SK-N-SH cells, and elucidate the underlying intracellular signaling.
MATERIALS AND METHODS: SK-N-SH cells were treated with an extremely low-dose (2-4 μM) of As2O3 alone or combined with 75 μg/ml resveratrol for further comparisons. Cell viability, apoptotic signaling as well as synergistic cytotoxic effects were estimated using the MTT assay, microscopy observation, flow cytometric analysis for loss of mitochondrial membrane potential (MMP) and reactive oxygen species (ROS), and typical quantitative western blotting analysis. Student's t-test, and one- and two-way analysis of variance (ANOVA) were used for examination of significant differences.
RESULTS: The combined treatment was more effective than single treatment of As2O3 or resveratrol alone in suppressing cell viability, which correlated with the elevation of ROS levels. The intracellular mechanisms of cytotoxicity of As2O3 plus resveratrol were revealed as ROS accumulation and relative decrease of MMP, leading to activation of caspase-3 and -9, but not of caspase-1, -7 and-8. Combination treatment reduced the expression of B-cell lymphoma 2 (BCL2), BH3 interacting domain death agonist (BID), and BCL-x/L.
CONCLUSION: Combined treatment at extremely low concentration of two agents from natural products, As2O3 and resveratrol, has high potential as a cocktail of anticancer drugs for neuroblastoma. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Apoptosis; arsenic trioxide; cytotoxicity; neuroblastoma; resveratrol

Mesh:

Substances:

Year:  2018        PMID: 30343279      PMCID: PMC6299785          DOI: 10.21873/cgp.20104

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  36 in total

1.  Huanglian, A chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells.

Authors:  X K Li; M Motwani; W Tong; W Bornmann; G K Schwartz
Journal:  Mol Pharmacol       Date:  2000-12       Impact factor: 4.436

2.  Dithiothreitol enhances arsenic trioxide-induced apoptosis in NB4 cells.

Authors:  J R Gurr; D T Bau; F Liu; S Lynn; K Y Jan
Journal:  Mol Pharmacol       Date:  1999-07       Impact factor: 4.436

3.  Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.

Authors:  X H Zhu; Y L Shen; Y K Jing; X Cai; P M Jia; Y Huang; W Tang; G Y Shi; Y P Sun; J Dai; Z Y Wang; S J Chen; T D Zhang; S Waxman; Z Chen; G Q Chen
Journal:  J Natl Cancer Inst       Date:  1999-05-05       Impact factor: 13.506

Review 4.  Expanding the use of arsenic trioxide: leukemias and beyond.

Authors:  Zhu Chen; Guo-Qiang Chen; Zhi-Xiang Shen; Guan-Lin Sun; Jian-Hua Tong; Zhen-Yi Wang; Sai-Juan Chen
Journal:  Semin Hematol       Date:  2002-04       Impact factor: 3.851

5.  Arsenite-induced apoptosis in cortical neurons is mediated by c-Jun N-terminal protein kinase 3 and p38 mitogen-activated protein kinase.

Authors:  U Namgung; Z Xia
Journal:  J Neurosci       Date:  2000-09-01       Impact factor: 6.167

Review 6.  Mechanisms of action of arsenic trioxide.

Authors:  Wilson H Miller; Hyman M Schipper; Janet S Lee; Jack Singer; Samuel Waxman
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

7.  Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: a role of Bcl-2.

Authors:  Sudhir Gupta; Leman Yel; Daniel Kim; Choong Kim; Sujata Chiplunkar; Sastry Gollapudi
Journal:  Mol Cancer Ther       Date:  2003-08       Impact factor: 6.261

8.  Localized pelvic neuroblastoma: excellent survival and low morbidity with tailored therapy--the 10-year experience of the French Society of Pediatric Oncology.

Authors:  Marc-David Leclair; Olivier Hartmann; Yves Heloury; Laurent Fourcade; Anne Laprie; Françoise Mechinaud; Caroline Munzer; Herve Rubie
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

9.  Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine.

Authors:  H Maeda; S Hori; H Ohizumi; T Segawa; Y Kakehi; O Ogawa; A Kakizuka
Journal:  Cell Death Differ       Date:  2004-07       Impact factor: 15.828

Review 10.  The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future.

Authors:  Andrew M Evens; Martin S Tallman; Ronald B Gartenhaus
Journal:  Leuk Res       Date:  2004-09       Impact factor: 3.156

View more
  2 in total

1.  Resveratrol modulates the apoptosis and autophagic death of human lung adenocarcinoma A549 cells via a p53‑dependent pathway: Integrated bioinformatics analysis and experimental validation.

Authors:  Yameng Fan; Jiaqiao Li; Yuxuan Yang; Xiaodan Zhao; Yamei Liu; Yude Jiang; Long Zhou; Yang Feng; Yan Yu; Yilong Cheng
Journal:  Int J Oncol       Date:  2020-08-07       Impact factor: 5.650

2.  Protective Effects of Jujubosides on 6-OHDA-Induced Neurotoxicity in SH-SY5Y and SK-N-SH Cells.

Authors:  Chao-Hsuan Chen; Pei-Chen Hsu; Shih-Wei Hsu; Kun-Ting Hong; Kai-Yuan Chen; Jie-Long He; Der-Yang Cho; Yun-Chi Wang; Wen-Shin Chang; Da-Tian Bau; Chia-Wen Tsai
Journal:  Molecules       Date:  2022-06-26       Impact factor: 4.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.